Bharat Biotech Submits Clinical Trial Data of Covaxin in Children to CDSC
3 years, 2 months ago

Bharat Biotech Submits Clinical Trial Data of Covaxin in Children to CDSC

News 18  

Bharat Biotech, which completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday. ?Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO?This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults,? Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on. As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.

Trial Bharat Bharat Biotech Covaxin Submits Clinical  bharat  submitted  cdsc  submits  clinical  sources  covaxin  data  children  trials  vaccine  phase  going  biotech  covid19  trial

History of this topic

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Nasal vaccine at govt centres in Delhi from Feb 15
1 year, 10 months ago

Nasal vaccine at govt centres in Delhi from Feb 15

Hindustan Times  

India’s first nasal vaccine for Covid-19, iNCOVACC, which was formally launched on Thursday, is likely to be made available at government centres in the national capital by mid-February, senior officials of the Delhi government said on Friday. Union health minister Mansukh Mandaviya and science and technology minister Jitendra Singh launched Bharat Biotech’s nasal Covid vaccine, iNCOVACC, on the occasion of …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26
1 year, 11 months ago

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26

India TV News  

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella said here on Saturday. In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use
2 years ago

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use

Live Mint  

World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation for restricted use in emergency situations in the age group of 18 and above. A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world's first …

CDSCO nod for Bharat Biotech’s COVID-19 intranasal vaccine under restricted use
2 years ago

CDSCO nod for Bharat Biotech’s COVID-19 intranasal vaccine under restricted use

The Hindu  

Bharat Biotech’s COVID-19 intranasal vaccine iNCOVACC has received Central Drugs Standard Control Organisation approval under restricted use in emergency situation for ages 18 and above for heterologous booster doses. Heterologous booster dose studies were conducted for safety and immunogenicity in about 875 subjects, with BBV154 intranasal vaccine administered post two doses of the two commonly administered COVID-19 vaccines. Product development …

Bharat Biotech’s nasal covid vax gets CDSCO’s nod as heterologous booster
2 years ago

Bharat Biotech’s nasal covid vax gets CDSCO’s nod as heterologous booster

Live Mint  

Pharma firm Bharat Biotech on Monday announced that its intranasal covid-19 vaccine iNCOVACC has received approval from the Central Drugs Standard Control Organization for people above 18 years of age as a heterologous booster dose under restricted emergency use in India. With this development, INCOVACC becomes world’s first intranasal vaccine to receive both primary series and heterologous booster approval, the …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

Govt, Bharat Biotech Deny ‘Shortcut’ in Covaxin Trials: What's the Controversy?
2 years, 1 month ago

Govt, Bharat Biotech Deny ‘Shortcut’ in Covaxin Trials: What's the Controversy?

The Quint  

The allegations: Here's a quick run through of the STAT report. It said that Bharat Biotech: Omitted data of some participants in the phase 1 trial when the study was published in a medical journal. The report says they had access to internal documents from the company, and they also quote people in the company, including Krishna Mohan, one of …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

COVID-19: Delhi High Court Closes Plea Challenging Centre's Permission For Clinical Trials Of Covaxin Among 2-18 Yrs Old
2 years, 3 months ago

COVID-19: Delhi High Court Closes Plea Challenging Centre's Permission For Clinical Trials Of Covaxin Among 2-18 Yrs Old

Live Law  

The Delhi High Court has disposed of a plea filed during the second wave of COVID-19 against Centre's permission for conducting Phase II and III clinical trials of Covaxin in the age group of 2 to 18 years. A division bench comprising of Chief Justice Satish Chandra Sharma and Justice Subramonium Prasad took note of the Supreme Court's judgment in …

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval
2 years, 3 months ago

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval

The Hindu  

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation for primary immunization against COVID-19 in 18+ age group for restricted use in emergencies, Health Minister Mansukh Mandaviya tweeted on Tuesday. Dr. Krishna Ella, chairman and managing director, Bharat Biotech, said: “iNCOVACC will be a global game changer in intra-nasal vaccines technology and delivery …

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
2 years, 4 months ago

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

Deccan Chronicle  

HYDERABAD: Bharat Biotech International Limited on Monday said its COVID-19 intranasal vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. Suchitra K Ella, Joint Managing Director, Bharat Biotech, …

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday
2 years, 4 months ago

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday

News 18  

Biological E. Ltd on Thursday said it has delivered 10 crore doses of its Covid-19 vaccine, Corbevax to the Centre so far which is expected to be available as a booster dose on the Cowin App in public and private vaccination centers from Friday. Corbevax was also approved by the Union Health Ministry as a heterologous Covid-19 booster dose under …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

Deccan Chronicle  

New Delhi: The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India Today  

The government has approved Biological E's Corbevax as a precautionary dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precautionary dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

India TV News  

Highlights Biological E's Corbevax has been approved as a booster or precaution dose. Covid vaccination: Biological E's Corbevax has been approved as a booster or precaution dose for those above the age of 18, and those who are fully vaccinated with either Covishield or Covaxin. "Corbevax will be considered as a precaution dose after completion of six months or 26 …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre
2 years, 5 months ago

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre

Firstpost  

Minister of State for Health Bharati Pravin Pawar said as on 19 July, 2022, a total of 200.34 crore COVID-19 vaccine doses have been administered to beneficiaries above 12 years of age in the country New Delhi: India has supplied 23.9 crore doses of coronavirus vaccine to 101 countries and UN entities in the form of grant, commercial export, or …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

India's cumulative Covid-19 vaccination nears 200 crore
2 years, 5 months ago

India's cumulative Covid-19 vaccination nears 200 crore

India Today  

The cumulative Covid-19 vaccine doses administered in the country neared the 200-crore mark on Saturday, the Union health ministry said. Over 14.94 lakh precaution doses of COVID-19 vaccines were given to people in the 18-59 age group till 10 pm, with the majority administered for free under the government's special 75-day drive 'COVID Vaccination Amrit Mahotsav'. The next phase of …

Free COVID-19 booster shots for all adults for 75 days from July 15 at government centres
2 years, 5 months ago

Free COVID-19 booster shots for all adults for 75 days from July 15 at government centres

The Hindu  

As part of the Azadi Ka Amrit Mahotsav celebrations, free precaution doses of COVID-19 vaccines will be available for all citizens above 18 years of age at government vaccination centres from July 15 for 75 days, Anurag Singh Thakur, Union Minister of Information and Broadcasting, announced on July 13, following a meeting of the Union Cabinet. India’s cumulative COVID-19 vaccination …

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years
2 years, 5 months ago

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years

News 18  

The NTAGI's Standing Technical Sub-Committee approved the use of COVID-19 vaccines Corbevax and Covaxin for children aged between five and 12 years, official sources said on Friday. Data of Biological E's Corbevax and Bharat Biotech's Covaxin for children aged between five and 12 years were reviewed in the STSC meeting held on June 16 and members decided that the vaccines …

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here
2 years, 5 months ago

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here

Live Mint  

Biological E's Corbevax and Bharat Biotech's Covaxin on July 8 received the nod from the National Technical Advisory Group on Immunisation's Standing Technical Sub-Committee for use among children aged between 5-12 years. The Drugs Controller General of India granted emergency use authorisation to the Biological E's Corbevax for 5-12 year old and Bharat Biotech's Covaxin for minors belonging to the …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 5 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

Serum Institute’s Covovax approved by DCGI for children aged 7 to 12 years
2 years, 5 months ago

Serum Institute’s Covovax approved by DCGI for children aged 7 to 12 years

Live Mint  

The Serum Institute Of India's Covid-19 vaccine Covovax has been approved on Tuesday by the Drugs Controller General of India for children between the age group of 7 and 12 years. The DCGI's nod for restricted emergency use in children came after the subject expert committee on Covid-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Govt Panel Recommends Emergency Approval for SII's Covovax for 7-11 Year Olds
2 years, 6 months ago

Govt Panel Recommends Emergency Approval for SII's Covovax for 7-11 Year Olds

News 18  

An expert panel of India's central drug authority on Friday recommended granting emergency use authorisation to Serum Institute's Covovax for children aged 7 to 11 years, official sources said. "The Subject Expert Committee on Covid-19 of the CDSCO deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years," …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 6 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed
2 years, 6 months ago

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed

News 18  

Bharat Biotech on Saturday said that the clinical Phase III trials of the nasal vaccine for Covid-19 have been completed and that the company will submit its data with Drugs Controller General of India next month. Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said, if everything is okay, then they will get permission to launch …

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief
2 years, 6 months ago

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief

Firstpost  

Dr Krishna Ella said that the company will submit its data with Drugs Controller General of India next month and If everything is okay, it will be the world’s first clinically proven nasal COVID-19 vaccine Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said that the clinical phase III trials of the COVID-19 nasal vaccine have …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
2 years, 6 months ago

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

Firstpost  

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity Hyderabad: Bharat Biotech International Limited on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multi-centre …

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap
2 years, 6 months ago

NTAGI to Review Covaxin, Corbevax Data for 6-12 Yrs Thursday, Discuss Reducing Booster Dose Gap

News 18  

Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months. The agenda for the NTAGI's Standing Technical Sub-Committee meeting includes a discussion on a study by the CMC Vellore …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Discover Related